Evidence map›Paper›PMID 33172035›Full record

ArticleBiomolecules2020

Ellagic Acid Prevents Dopamine Neuron Degeneration from Oxidative Stress and Neuroinflammation in MPTP Model of Parkinson's Disease.

Mustafa T Ardah, Greeshma Bharathan, Tohru Kitada, M Emdadul Haque

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 57 citations in OpenAlex.

  1. Ellagic acid counteracts mercury chloride-induced oxidative stress and thiol oxidation in Drosophila melanogaster.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Therapeutic Potential of Ellagic Acid in Liver Diseases.Molecules (Basel, Switzerland) · 2025
    Review
  13. Review
  14. Article
  15. Lead Phytomolecules for Treating Parkinson's Disease.Central nervous system agents in medicinal chemistry · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mustafa T ArdahDepartment of Biochemistry, College of Medicine and Health Sciences, UAEU, Al Ain, UAE.
Greeshma BharathanDepartment of Biochemistry, College of Medicine and Health Sciences, UAEU, Al Ain, UAE.
Tohru KitadaOtawa-Kagaku Service, Parkinson's Clinic and Research, Kamakura 247-0061, Japan.
M Emdadul HaqueDepartment of Biochemistry, College of Medicine and Health Sciences, UAEU, Al Ain, UAE.
United Arab Emirates University · AE

Funding

College of Medicine and Health Sciences, United Arab Emirates University 31M259
6 · The paper itself

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative diseases and is characterized by progressive dopaminergic neurodegeneration in the substantia nigra pars compacta area. In the present study, treatment of EA for 1 week at a dose of 10 mg/kg body weight prior to MPTP (25 mg/kg body weight) was carried out. MPTP administration caused oxidative stress, as evidenced by decreased activities of superoxide dismutase and catalase, and the depletion of reduced glutathione with a concomitant rise in the lipid peroxidation product, malondialdehyde. It also significantly increased the pro-inflammatory cytokines and elevated the inflammatory mediators like cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in the striatum. Immunohistochemical analysis revealed a loss of dopamine neurons in the SNc area and a decrease in dopamine transporter in the striatum following MPTP administration. However, treatment with EA prior to MPTP injection significantly rescued the dopaminergic neurons and dopamine transporter. EA treatment further restored antioxidant enzymes, prevented the depletion of glutathione and inhibited lipid peroxidation, in addition to the attenuation of pro-inflammatory cytokines. EA also reduced the levels of COX-2 and iNOS. The findings of the present study demonstrate that EA protects against MPTP-induced PD and the observed neuroprotective effects can be attributed to its potent antioxidant and anti-inflammatory properties.

Indexed as

Dopaminergic NeuronsEllagic AcidOxidative Stress1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAntioxidantsCorpus StriatumCyclooxygenase 2Disease Models, AnimalDopamine Plasma Membrane Transport ProteinsLipid PeroxidationMaleMiceNeuroinflammatory DiseasesNeuroprotective AgentsNitric Oxide Synthase Type II1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAntioxidantsCyclooxygenase 2Dopamine Plasma Membrane Transport ProteinsEllagic AcidNeuroprotective AgentsNitric Oxide Synthase Type IIellagic acidneurodegenerationneurotoxicityParkinson’s disease

Identifiers

PMID33172035
PMCPMC7694688
OpenAlexW3096602921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.